These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37149036)

  • 1. Bone Mineral Density Response to Long-Term Bisphosphonate Treatment and Discontinuation in a Real-World Clinical Service.
    Powell DE; Evans SF; Rakieh C
    Endocr Pract; 2023 Aug; 29(8):601-605. PubMed ID: 37149036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.
    Saag K; Cosman F; De Villiers T; Langdahl B; Scott BB; Denker AE; Pong A; Santora AC
    Osteoporos Int; 2021 Sep; 32(9):1879-1888. PubMed ID: 33606045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
    Kashii M; Kamatani T; Nagayama Y; Miyama A; Tsuboi H; Ebina K
    Osteoporos Int; 2023 Mar; 34(3):563-572. PubMed ID: 36585509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.
    Roberts J; Castro C; Moore AE; Fogelman I; Hampson G
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):509-15. PubMed ID: 26715263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
    Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
    J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C; Günther B; Popp AW; Perrelet R; Hans D; Lippuner K
    Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bone mineral density of osteoporotic and osteopenia menopausal women treated with oral bisphosphonates before stopping the treatment and 1 year after drug holiday period.
    Rizi MM; Salari A; Salesi M; Rasooli L; Karimifar M
    Clin Rheumatol; 2024 Apr; 43(4):1375-1379. PubMed ID: 38347325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
    Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
    Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in QUS and BMD measurements with antiresorptive therapy: a two-year longitudinal study.
    Frost ML; Blake GM; Fogelman
    Calcif Tissue Int; 2001 Sep; 69(3):138-46. PubMed ID: 11683528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer.
    Hirano A; Inoue H; Ogura K; Hattori A; Yukawa H; Sakaguchi S; Matsuoka A; Tanaka N; Kodera A; Kamimura M; Naritaka Y; Shimizu T
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e238-e242. PubMed ID: 29932305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
    Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
    Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting.
    Chiha M; Myers LE; Ball CA; Sinacore JM; Camacho PM
    Endocr Pract; 2013; 19(6):989-94. PubMed ID: 24013976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
    Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
    Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J; Brown C; Moore AEB; Min SS; Hampson G
    Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.